Does ibogaine work for opioid addiction?

What the evidence shows

Opioid use disorder has more human data behind it than any other ibogaine indication. A 2018 case series of 191 patients documented rapid resolution of opioid withdrawal after a single treatment.^[1] A prospective New Zealand study following opioid-dependent patients reported reduced use sustained at 12 months in a meaningful subset, with the best outcomes among those who avoided early relapse.^[2] The mechanism fits: ibogaine and its long-lasting metabolite noribogaine act on opioid and NMDA systems in ways that plausibly blunt withdrawal.^[3]

What it does not prove

No completed randomized controlled trial exists, so this is promising early evidence, not settled science. "Interrupts withdrawal" is well supported; "cures addiction" is not. Long-term abstinence from a single dose is the exception rather than the rule, and it tracks strongly with aftercare. The federally funded Texas IMPACT trial is designed to produce the controlled opioid-and-trauma data the field still lacks.^[4]

The switchover problem (fentanyl, methadone, Suboxone)

Timing is a safety issue, not a detail. Long-acting opioids interfere with treatment and raise risk, so clinics transition patients onto a short-acting opioid before dosing and wait out a washout period. In practice that means longer, more expensive programs for methadone and Suboxone cases, and careful timing for fentanyl because of how it distributes in the body. Getting this wrong risks precipitated withdrawal. See our page on ibogaine for fentanyl.

Why opioid patients face the highest cardiac risk

The safety data is consistent that ibogaine deaths concentrate in opioid-dependent patients rather than in people treated for other reasons.^[5] That makes the clinic's medical tier non-negotiable for detox: pre-treatment EKG and electrolyte screening, continuous cardiac monitoring during dosing, ACLS-trained staff, and a real emergency plan. A ceremony-style retreat is the wrong setting for an opioid detox.